Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference PR Newswire - Thu Feb 26, 3:35PM CST

WASHINGTON , Feb. 26, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2026 Citizens Life Sciences Conference in Miami...

VNDA : 8.60 (+3.86%)
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis PR Newswire - Wed Feb 25, 6:18AM CST

WASHINGTON , Feb. 25, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics...

VNDA : 8.60 (+3.86%)
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation PR Newswire - Fri Feb 20, 4:59PM CST

WASHINGTON , Feb. 20, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets,...

VNDA : 8.60 (+3.86%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA PR Newswire - Thu Feb 12, 5:56PM CST

NEW YORK , Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are...

VNDA : 8.60 (+3.86%)
Vanda: Q4 Earnings Snapshot AP - Wed Feb 11, 3:21PM CST

Vanda: Q4 Earnings Snapshot

VNDA : 8.60 (+3.86%)
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results PR Newswire - Wed Feb 11, 3:01PM CST

WASHINGTON , Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December...

VNDA : 8.60 (+3.86%)
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 PR Newswire - Wed Feb 4, 5:01PM CST

Conference Call and Webcast to Follow

VNDA : 8.60 (+3.86%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA PR Newswire - Thu Jan 29, 9:00AM CST

NEW YORK , Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA).  Such investors...

VNDA : 8.60 (+3.86%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA PR Newswire - Thu Jan 22, 9:00AM CST

NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are...

VNDA : 8.60 (+3.86%)
Lost Money on Vanda Pharmaceuticals Inc. (VNDA)? Contact Levi & Korsinsky About Fraud Investigation Newsfile - Thu Jan 15, 10:32AM CST

New York, New York--(Newsfile Corp. - January 15, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:...

VNDA : 8.60 (+3.86%)

Barchart Exclusives

Love Dividends? 1 Stock to Buy Now With a Yield Over 6%. Barchart - Thu Feb 26, 6:30PM CST
Even amid volatility, Pfizer keeps rewarding shareholders year after year. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot